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Prognostic impact of immunohistochemical
expression of CK7 and CK20 in curatively
resected ampulla of Vater cancer
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Abstract
Background: In the consideration of ampullary adenocarcinoma, T stage, lymph node metastases, perineural
invasion, tumor differentiation, pancraticobiliary type, and lymph node ratio are considered prognostic factors.
The objectives of this study were to investigate surgical outcomes and the clinicopathological predictors affecting
survival and recurrence, and to examine the prognostic roles of histopathological subtype and immunohistochemical
markers.
Methods: From April 2006 to September 2012, 37 patients who underwent curative resection of ampullar of Vater
adenocarcinoma were enrolled in this study. A retrospective review was performed based on medical records.
Immunohistochemical expression, histopathological type and clinicopathologic factors were analyzed.
Results: The 5-year overall survival rates and disease-free survival rates after surgery were 77.4 and 75.7 %, respectively.
Multivariate Cox regression analysis showed that advanced T stage (p = 0.019) and positive expression of Cytokeratin 7
(CK7) with negative expression of Cytokeratin 20 (CK20) (p = 0.046) were identified as significant independent factors
related to survival, and poor differentiation (p = 0.031) significantly influenced disease-free survival in multivariate analysis.
Conclusions: Advanced T stage is a significant prognostic factor affecting survival in ampullary adenocarcinoma. Also,
positive expression of CK7 with negative expression of CK20 is an independent factor related to overall survival.
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Background
Adenocarcinoma of the ampulla of Vater (AoV) is a rela-
tively rare neoplasm accounting for 0.5 % of all gastro-
intestinal malignancies and about 30 % of all cases
requiring pancreaticoduodenectomy [1–3]. Adenocarcin-
oma of the AoV is a type of periampullary carcinoma
with a better prognosis than other periampullary carcin-
omas [4, 5]. Compared with other tumors, ampullary
adenocarcinomas tend to be detected relatively early.
Therefore, ampullary adenocarcinomas have a higher
resection rate at the time of diagnosis than other
periampullary carcinoma, and they have a better prog-
nosis compared with pancreatic and bile duct malig-
nancies [5–7].
AoV adenocarcinomas can be categorized into two
major histologic types. Intestinal type adenocarcinomas of
the duodenal papilla originate from the intestinal mucosa
covering the papilla and evolve through an adenoma-
dysplasia-carcinoma sequence. Pancreaticobiliary type
adenocarcinomas are derived from ductal epithelium that
penetrates the duodenal muscularis propria containing the
distal common bile duct, the distal pancreatic duct, or the
common ampullary channel [8, 9]. Apparently, pancreati-
cobiliary type ampullary adenocarcinoma is associated
with lower survival rates [10, 11]. Cytokeratin 7 (CK7) and
Cytokeratin 20 (CK20) are reliable and well-characterized
immunohistochemical markers, and are usually helpful in
distinguishing intestinal type and pancreaticobiliary type
adenocarcinoma. According to a previous study, CK7 was
expressed in 91.4 % of the pancreaticobiliary type ampul-
lary carcinomas, and CK20 expression was positive in
about 90 % of the intestinal type ampullary carcinomas,
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but was generally negative in the pancreaticobiliary type
[10]. However, the expression profiles of CK7 and CK20
in relation to tumor histotype and prognosis have not
been carefully investigated in ampullary adenocarcinomas.
The objectives of this study were to investigate surgical
outcomes, the clinicopathological predictors affecting sur-
vival and recurrence, and the prognostic roles of histo-
pathological subtype and immunohistochemical markers
of resected ampullary adenocarcinoma.
Methods
Patients
Patients who underwent curative resection of AoV adeno-
carcinoma at Pusan National University Hospital from
April 2006 to September 2012 were enrolled in this study.
A retrospective review was performed based on medical
records. Patients who underwent R1 resection or palliative
resection and patients with stage IV disease were excluded,
as well as patients with other types of carcinomas. Finally,
37 patients were included. This retrospective study was ap-
proved by the institutional review board at Pusan National
University Hospital Clinical Trial Center (IRB No.2015053),
and written informed consent was obtained from all partici-
pants. Twenty-eight patients underwent pylorus preserving
pancreaticodoudenectomy, and 9 patients underwent con-
ventional pancreaticoduodenectomy. The following clinical
information was retrospectively reviewed from patient
records: sex, age, T stage, lymph node metastases, AJCC
stage, lymphovascular invasion, perineural invasion, tumor
size, tumor differentiation, preoperative carbohydrate anti-
gen 19–9 (CA 19–9), preoperative carcinoembryonic
antigen (CEA), postoperative pancreatic fistula, adjuvant
chemotherapy or radiotherapy, histopathological subtype,
and immunohistochemical markers. Histological diagnosis
was examined by a pathologist who specializes in hepa-
tobiliary pathology. Immunohistochemistry for these
antibodies were performed on formalin-fixed embedded
sections on the fully automated Bond Max automatic
slide stainer (Leica Microsystems, Bannockburn, IL,
USA). Primary antibodies were prediluted monoclonal
antibodies clone against CK7 and CK20 proteins (CK7
clone OV-TL12/30; CK20 PW31). Classification of
adenocarcinoma into intestinal or pancreaticobiliary types
was performed using cytologic and architectural features
according to criteria revised by Albores-Saavedra et al.
[12]. CK7 and CK20 expression was established using the
percentage of immunoreactive cells calculated by the
number of immunoreactive cells over the total number of
tumor cells. Cases showing greater than 5 % tumor cell
positivity were regarded as positive (Fig. 1) [8].
Statistical analysis
We analyzed clinicopathological features, disease-free
survival, and overall survival rates. Overall survival
rate was measured from the date of surgery to the date
of death from any cause; locoregional recurrences,
distant metastases and second primary cancer were
ignored. Disease-free survival was measured from the
date of surgery to the date of second cancer, locoregio-
nal recurrence, distant metastases or death from any
cause. Categorical variables were compared using the
chi-square test or Fisher’s exact test. Overall survival
Fig. 1 Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) expression in ampulla of Vater adenocarcinoma. a, b CK7 and CK 20 in one patient displaying
intestinal subtype adenocarcinoma. a CK7 negative and b CK20 positive. c, d one patient displaying pancreaticobiliary type adenocarcinoma. c CK7
positive and d CK20 negative
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and disease-free survival were estimated according to
the Kaplan-Meier method, and survival differences
were evaluated using the log-rank test. Both univariate
and multivariate Cox proportional hazards regression
models were used to identify risk factors for recur-
rence or death. Risk factors in univariate models were
included in multivariate models. P values less than
0.05 were considered statistically significant.
Results
Clinicopathological features are summarized in Table 1.
The cohort consisted of 37 patients with pathological
diagnoses of radically resected adenocarcinoma of the
ampulla of Vater. The median age of the patients was
63 years old (range: 47–80 years), and 19 of the patients
were females (51.4 %). Fourteen patients (37.8 %) were
classified as T1, 8 patients (21.6 %) were classified as T2,
14 patients (37.8 %) were classified as T3, and 1 patient
(2.7 %) was classified as T4. Nodal metastasis was
present in 6 (16.2 %) of the tumor specimens. The inci-
dence of T1 or T2 AoV adenocarcinoma was slightly
high. Tumor size ranged from 0.9 to 7.1 cm and aver-
aged 2.58 ± 1.49 cm. Lymphovascular invasion was found
in 6 patients (16.2 %), and 7 tumors (18.9 %) showed
perineural invasion. 6 tumors were poorly differentiated.
17 patients underwent adjuvant therapy (chemotherapy
or concurrent chemoradiotherapy)
The median duration of follow-up after surgery was
41 months (range, 11–97). The 5-year overall survival
rate after surgery was 77.4 %. The 5-year disease-free
survival rate was 75.7 %. CK7 positive and CK20 nega-
tive (CK7+/CK20-) was significantly more common in
the pancreaticobiliary type than in the intestinal type
according to the chi-square test (p = 0.005). Sex, age, T
stage, lymph node metastases, AJCC stage, lymphovas-
cular invasion, perineural invasion, tumor size, tumor
differentiation, CA 19–9, CEA, and postoperative pan-
creatic fistula were similar for CK7+/CK20- and non-
CK7+/CK20- patients. By univariate analysis, overall
survival in this study was found to be influenced signifi-
cantly by advanced T stage (T3 or T4) (p = 0.015), lymph
node metastases (p = 0.021), positive lymphvascular inva-
sion (p = 0.024), positive perineural invasion (p = 0.041),
poor differentiation (p = 0.013), AJCC stage (p = 0.021)
and CK7+/CK20- (p = 0.036) (Table 2). Figure 2 shows
overall survival using a Kaplan-Meier survival plot in pa-
tients with resected ampulla of Vater adenocarcinoma ac-
cording to immunohistochemical expression. Multivariate
Cox regression analysis of factors identified by univariate
analysis showed that advanced T stage and CK7+/CK20-
were identified as significant independent factors related
to survival (Table 3). In terms of disease-free survival, uni-
variate analysis showed that advanced T stage (T3 or T4)
(p = 0.011), lymph node metastases (p = 0.010), positive
lymphvascular invasion (p = 0.009), positive perineural
invasion (p = 0.019), poor differentiation (p < 0.001), AJCC
stage (p = 0.010), pancreaticobiliary type (p = 0.046) and
adjuvant therapy (p = 0.042) significantly influenced
recurrence (Table 2). Multivariate analysis of factors
identified by univariate analysis showed that poor dif-
ferentiation (p = 0.031) significantly influenced disease-
free survival (Table 4).
Table 1 Demographics and clinical characteristics of patients
with ampullary adenocarcinoma
Variables
Total number 37 (100 %)
Sex
Male 18 (48.6 %)
Female 19 (51.4 %)
Age, years 62.57 ± 8.22
T stage
T1 14 (37.8 %)
T2 8 (21.6 %)
T3 14 (37.8 %)
T4 1 (2.7 %)
N stage
N0 31 (83.8 %)
N1 6 (16.2 %)
Overall stage
IA 14 (37.8 %)
IB 6 (16.2 %)
IIA 11 (29.7 %)
IIB 5 (13.5 %)
III 1 (2.7 %)
Tumor size (cm) 2.58 ± 1.49
CA19-9 (U/ml) 459.54 ± 1727.30
CEA (ng/ml) 4.03 ± 5.65
Lymphovascular invasion
No 31 (83.8 %)
Yes 6 (16.2 %)
Perineural invasion
No 30 (81.1 %)
Yes 7 (18.9 %)
Differentiation
Well/Moderately 31 (83.8 %)
Poorly 6 (16.2 %)
Adjuvant therapy
No 20 (54.0 %)
Yes 17 (46.0 %)
CA19-9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen
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Table 2 Univariate analysis for predictive factors influencing overall survival and disease-free survival after curative resection
Variables N 5 years
survival rate
Overall survival 5 years
survival rate
Disease-free survival
Hazard ratio P value Hazard ratio P value
Sex
Male 18 87.2 2.33 (0.45–12.05) 0.311 77.8 1.07 (0.28–3.99) 0.919
Female 19 68.0 73.7
Age, years
< 60 14 80.0 1.79 (0.34–9.21) 0.489 78.6 1.27 (0.32–5.09) 0.733
≥ 60 23 75.9 73.9
Subtype
Intestinal 17 93.3 8.45 (0.99–71.61) 0.051 94.1 8.34 (1.04–66.88) 0.046
Pancreaticobiliary 20 60.5 60.0
CK7 +/CK20 -
No 19 93.3 9.74 (1.16–81.89) 0.036 89.5 4.31 (0.89–20.77) 0.069
Yes 18 57.5 61.1
CDX2
No 20 75.2 1.26 (0.28–5.68) 0.764 75.0 1.02 (0.28–3.81) 0.972
Yes 16 79.3 75.0
T stage
T1, T2 22 95.2 13.94 (1.66–117.03) 0.015 95.5 14.81 (1.85–118.92) 0.011
T3, T4 15 45.4 46.7
Lymph node metastasis
No 31 88.4 6.00 (1.30–27.58) 0.021 83.9 5.69 (1.52–21.30) 0.010
Yes 6 33.3 33.3
Lymphovascular invasion
No 31 85.1 5.89 (1.27–27.38) 0.024 83.9 6.06 (1.58–23.28) 0.009
Yes 6 31.3 33.3
Perineural invasion
No 30 84.0 4.83 (1.07–21.87) 0.041 83.3 4.88 (1.29–18.40) 0.019
Yes 7 47.6 42.9
Size
< 2 cm 14 83.1 1.92 (0.37–9.94) 0.436 85.7 2.34 (0.49–11.25) 0.290
≥ 2 cm 23 73.8 69.6
Differentiation
Well/mod 31 86.0 8.18 (1.57–42.67) 0.013 87.1 12.29 (3.06–48.31) <0.001
Poorly 6 0 16.7
Stage
I and IIA 31 88.4 6.00 (1.30–27.58) 0.021 83.9 5.69 (1.52–21.30) 0.010
IIB and III 6 33.3 33.3
Ca19-9 (U/ml)
< 37 12 70.0 0.66 (0.13–3.28) 0.611 66.7 0.40 (0.09–1.81) 0.236
≥ 37 20 84.0 85.0
CEA (ng/ml)
< 5 27 83.2 1.28 (0.14–11.54) 0.826 81.5 1.37 (0.16–11.74) 0.774
≥ 5 4 75.0 75.0
Pancreatic fistula
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Discussion
Adenocarcinoma of the ampulla of Vater is a relatively
rare neoplasm. In contrast to pancreatic cancer, at least
80 % of patients with ampullary adenocarcinoma are can-
didates for potentially curative resection [13]. Standard
surgical therapies include pancreaticoduodenectomy or
ampullectomy in patients for whom radical resection is
not feasible. High resectability rate and early detection of
carcinoma due to early symptom onset, such as obstruct-
ive jaundice, are more closely related to a better prognosis
in this carcinoma than in distal bile duct carcinoma or
pancreatic head carcinoma [5, 9, 14, 15]. According to
previous studies, 5-year survival rates have been reported
in the range of 38 to 68 % [15–23]. Similarly, in this study,
the 5-year survival rate in patients who underwent a rad-
ical operation was 77.4 %. Many studies have examined
the prognosis of ampullary adenocarcinoma. Several clini-
copathological factors have been reported to influence
prognosis after curative resection. Previous studies have
reported that the depth of tumor infiltration (T stage) is
an important prognostic factor [15, 16]. Also, prognostic
factors for ampullary adenocarcinoma following curative
surgery have been reported as lymph node metastases
[15–17, 24], perineural invasion [16, 18, 20, 23], tumor dif-
ferentiation [18, 25], pancraticobiliary type [9, 11], and
lymph node ratio [24, 26]. In this study, our multivariate
analysis showed that advanced T stage and CK7+/CK20-
were identified as significant independent factors related
to survival, and poor differentiation significantly influ-
enced the rate of disease-free survival.
In recent studies, the pancreatobiliary subtype of ampul-
lary adenocarcinomas demonstrated more node metastases
and was associated with a poorer prognosis than was ob-
served with the intestinal subtype [9, 11, 27, 28]. However,
some studies reported no significant prognostic differences
between the intestinal subtype and the pancreaticobiliary
subtype [2, 29, 30]. In the present study, overall survival
was not found to be significantly shorter for pancratico-
biliary subtype ampullary adenocarcinoma in univariate
analysis. With regard to immunohistologic results,
CK7+/CK20- was identified as a factor influencing
survival in multivariate analysis.
Table 2 Univariate analysis for predictive factors influencing overall survival and disease-free survival after curative resection
(Continued)
No 21 77.2 0.88 (0.20–3.95) 0.872 71.4 0.59 (0.15–2.35) 0.453
Yes 16 77.9 81.3
Adjuvant therapy
No 20 90.0 3.67 (0.70–19.02) 0.122 90.0 5.11 (1.06–24.68) 0.042
Yes 17 58.2 58.8
CK7 Cytokeratin 7, CK20 Cytokeratin 20, CA19-9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen
Fig. 2 Overall survival in patients with resected ampulla of Vater adenocarcinoma according to immunohistochemical expression
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Generally, the immunohistochemistry of intestinal type
adenocarcinomas is CK7 negative and CK20 positive,
whereas the immunohistochemistry of pancreaticobiliary
type adenocarcinomas is CK7 positive and CK20 negative,
as is pancreatic ductal epithelium [29]. Zhou et al. [29]. Re-
ported a close correlation between tumors characterized by
histological features and those characterized by cytokeratin
expression. According to a study by Morini et al. [10], of 72
cases, there was a total of 31 cases of the intestinal type and
35 cases of the pancreaticobiliary type. They commented
that CK20 was an independent factor related to prognosis,
however, there was no significant prognostic difference
between the intestinal type and the pancreaticobiliary type.
In the present study, we identified a total of 17 cases of the
intestinal type and 20 cases of the pancreaticobiliary type.
The pancreatobiliary type was found to be more com-
mon than the intestinal type. Of a total of 17 cases of
the intestinal type, 2 cases were CK7- and CK20+, 4
cases were CK7 + and CK20-, 7 cases were CK7+ and
CK20+, and 4 cases were CK7- and CK20-. There was
also a total of 20 cases of the pancreaticobiliary type: 1 case
for CK7-/CK20+, 14 for CK7+/CK20-, 0 for CK7+/CK20+,
and 5 for CK7-/CK20-. In this study, the difference in
survival rates according to histologic type was not signifi-
cant. However, immunohistochemical results, in the case of
CK7+/CK20-, were identified as a factor affecting survival
in multivariate analysis. The prognosis according to histo-
logic subtype of ampullary adenocarcinoma has also been
well described in several previous studies. However, there
are few studies that include a comparative analysis
according to immunohistochemical markers. Immuno-
histochemical results are essential for the determination of
the histological subtype of ampullary adenocarcinoma. But,
expression of immunohistochemical marker and histo-
logical type are not always matched. Therefore, examin-
ation of prognosis as dependent on immunohistochemical
markers may be meaningful for predicting the outcome of
ampullary adenocarcinoma. Also, a precise immunochemi-
cal study of subtyping may provide a valuable tool for
better defining ampullary adenocarcinoma, contributing to
more accurate predictions of prognosis [10]. In the present
study, the identification of CK7+/CK20- as a factor affect-
ing survival in multivariate analysis confirms its role as a
pathological indicator predicting a clinical outcome. This
immunohistochemical result deserves further research as a
potential marker for selection of patients for adjuvant
chemotherapy.
The limitations of this study include its retrospective
nature and the limited number of patients due to the
rarity of ampullary carcinoma. Also, we did not analyze
other immunohistochemical subtypes by testing expres-
sion of MUC1, MUC2, etc. Additionally, we could not
control for treatment received after resection, such as
chemotherapy or concurrent chemoradiotherapy, which
may have influenced overall survival.
Conclusions
In conclusion, our study indicates that advanced T stage is
a significant prognostic factor affecting survival, and poor
Table 3 Multivariate analysis of overall survival in patients with
ampullary adenocarcinoma
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Table 4 Multivariate analysis of disease-free survival in patients
with ampullary adenocarcinoma
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differentiation is a significant prognostic factor affecting
disease-free survival in ampullary adenocarcinoma. Also,
CK7+/CK20- expression is an independent factor related
to overall survival.
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